This site is intended only for healthcare professionals resident in Egypt
Second- Line and beyond
The demographic characteristics of the overall study population were: median age 59 years (range: 26 to 90 years), age ≥ 65 years (35%), 59% female, 49% White, 44% Asian and 0.3% Black. The ECOG performance status at baseline was 0 or 1 in 96% of patients. The majority of patients had adenocarcinoma (95%) and never smoked (59%). CNS metastases were present in 26% (n=78) of patients: of these, 30 patients had measurable CNS lesions.2
† Assessed by BICR according to RECIST v1.1.
BICR: Blinded Independent Central Review; BID=twice daily; CNS: central nervous system; ECOG PS: Eastern Cooperative Oncology Group Performance Status; QD: once daily; RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1; HR: hazard ratio; PFS: progression-free survival.
The LORBRENA™ global registrational study: Baseline characteristics2
§By independent central review and includes measurable and non-measurable baseline central nervous system lesions.2
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ""No"", you will be redirected to Pfizer.com, the global Pfoizer websitee.
I confirm that i am a healthcare professional resident in Egypt.